Verrica Pharmaceuticals Inc.
VRCA
$5.23
-$0.12-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.70M | 3.44M | 344.00K | -1.78M | 5.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.70M | 3.44M | 344.00K | -1.78M | 5.18M |
| Cost of Revenue | 2.34M | 2.72M | 12.47M | 435.00K | 3.86M |
| Gross Profit | 10.36M | 718.00K | -12.12M | -2.22M | 1.32M |
| SG&A Expenses | 8.85M | 8.85M | 9.88M | 16.08M | 16.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.19M | 11.57M | 11.67M | 18.92M | 20.38M |
| Operating Income | 1.51M | -8.13M | -11.33M | -20.70M | -15.21M |
| Income Before Tax | 204.00K | -9.74M | -16.20M | -22.86M | -17.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 204.00K | -9.74M | -16.20M | -22.86M | -17.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 204.00K | -9.74M | -16.20M | -22.86M | -17.19M |
| EBIT | 1.51M | -8.13M | -11.33M | -20.70M | -15.21M |
| EBITDA | 1.64M | -7.99M | -11.14M | -20.46M | -14.95M |
| EPS Basic | 0.02 | -1.03 | -2.41 | -4.88 | -3.70 |
| Normalized Basic EPS | 0.01 | -0.64 | -1.50 | -3.05 | -2.31 |
| EPS Diluted | 0.02 | -1.03 | -2.41 | -4.88 | -3.70 |
| Normalized Diluted EPS | 0.01 | -0.64 | -1.50 | -3.05 | -2.31 |
| Average Basic Shares Outstanding | 9.49M | 9.48M | 6.73M | 4.68M | 4.65M |
| Average Diluted Shares Outstanding | 9.49M | 9.48M | 6.73M | 4.68M | 4.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |